about
Targeting TLR-4 with a novel pharmaceutical grade plant derived agonist, Immunomax®, as a therapeutic strategy for metastatic breast cancer.Regulation of the target protein (transgene) expression in the adenovirus vector using agonists of toll-like receptors.Primary 4T1 tumor resection provides critical "window of opportunity" for immunotherapy.Anticancer Mechanisms in Two Murine Bone Marrow-Derived Dendritic Cell Subsets Activated with TLR4 Agonists.Elevated pre-activation basal level of nuclear NF-κB in native macrophages accelerates LPS-induced translocation of cytosolic NF-κB into the cell nucleus
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Alexander Bagaev
@ast
Alexander Bagaev
@en
Alexander Bagaev
@es
Alexander Bagaev
@nl
type
label
Alexander Bagaev
@ast
Alexander Bagaev
@en
Alexander Bagaev
@es
Alexander Bagaev
@nl
prefLabel
Alexander Bagaev
@ast
Alexander Bagaev
@en
Alexander Bagaev
@es
Alexander Bagaev
@nl
P106
P31
P496
0000-0002-8680-854X